Cognetivity Neurosciences (CSE: CGN) continues to expand upon its global reach, this morning announcing its first step into the Asian market via a pilot program in Singapore. The pilot comes via a senior care network, a leading provider in its category.
The arrangement will see the company enter a paid pilot program with lions Befrienders Service Association, who’s network currently consists of over 7,600 at-risk seniors. The firm presently operates five active ageing centres, five senior activity centres, three cluster supports, and two group homes, in addition to providing home-based personal care services.
The initial pilot program will be for a period of three months, during which time Cognetivity’s flagship product, the CognICA brain health screening platform, will be used with a selected group to evaluate those suffering from or at risk of cognitive impairment. The tool is to be used to test the efficacy of different treatment programs that are conducted to assist in reducing such impairments.
Sponsored · Antimony Resources
Provided the phase one pilot program is successful, the product would then be rolled out in a commercial deployment to provide testing for over 1,250 seniors.
“Brain health is an enormous global issue that is best addressed proactively. With deployments of the CognICA™ platform now spanning four continents, we’re thrilled to be increasingly recognized as an integral part of the long term solution,” commented CEO Sina Habibi.
Cognetivity Neuroscience last traded at $0.275 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
